Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Cedar Pollen Allergy Overview | 6 | 1 |
| Therapeutics Development | 7 | 2 |
| Pipeline Products for Cedar Pollen Allergy Overview | 7 | 1 |
| Pipeline Products for Cedar Pollen Allergy Comparative Analysis | 8 | 1 |
| Cedar Pollen Allergy Therapeutics under Development by Companies | 9 | 1 |
| Cedar Pollen Allergy Therapeutics under Investigation by Universities/Institutes | 10 | 1 |
| Cedar Pollen Allergy Pipeline Products Glance | 11 | 3 |
| Late Stage Products | 11 | 1 |
| Clinical Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Cedar Pollen Allergy Products under Development by Companies | 14 | 1 |
| Cedar Pollen Allergy Products under Investigation by Universities/Institutes | 15 | 1 |
| Cedar Pollen Allergy Companies Involved in Therapeutics Development | 16 | 6 |
| ALK-Abello A/S | 16 | 1 |
| Astellas Pharma Inc. | 17 | 1 |
| Circassia Pharmaceuticals Plc | 18 | 1 |
| Immunomic Therapeutics, Inc. | 19 | 1 |
| Japan Tobacco Inc. | 20 | 1 |
| REGiMMUNE Corporation | 21 | 1 |
| Cedar Pollen Allergy Therapeutics Assessment | 22 | 7 |
| Assessment by Monotherapy Products | 22 | 1 |
| Assessment by Combination Products | 23 | 1 |
| Assessment by Target | 24 | 1 |
| Assessment by Route of Administration | 25 | 2 |
| Assessment by Molecule Type | 27 | 2 |
| Drug Profiles | 29 | 13 |
| ASP-4070 Drug Profile | 29 | 2 |
| Biologic for Cedar Pollen Allergy Drug Profile | 31 | 1 |
| JCC-LAMP-Vax Drug Profile | 32 | 1 |
| RGI-1001 Drug Profile | 33 | 1 |
| standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine Drug Profile | 34 | 5 |
| TO-206 Drug Profile | 39 | 1 |
| Vaccine for Cedar Pollen Allergy Drug Profile | 40 | 1 |
| Vaccine for Japanese Cedar Pollen Allergy Drug Profile | 41 | 1 |
| Cedar Pollen Allergy Dormant Projects | 42 | 1 |
| Cedar Pollen Allergy Product Development Milestones | 43 | 3 |
| Featured News &Press Releases | 43 | 1 |
| Aug 07, 2015: ALK s partner for Japan reports positive Phase II/III trial results for Japanese Cedar SLIT-tablet | 43 | 1 |
| Mar 09, 2015: Immunomic Therapeutics to Present at BIO-Europe Annual Conference | 43 | 1 |
| Feb 20, 2015: Immunomic Therapeutics to Present Data on Its Proprietary LAMP Vaccine Platform at 2015 American Academy of Allergy, Asthma and Immunology Meeting | 43 | 1 |
| Apr 24, 2013: Immunomic Therapeutics Announces Interim Data Analysis Of Phase I Study To Treat Japanese Red Cedar Allergy | 44 | 1 |
| Nov 08, 2012: Immunomic Therapeutics Doses First Patient In Phase I Clinical Trial Of JRC-LAMP-Vax Vaccine To Treat Japanese Red Cedar Allergy | 45 | 1 |
| Appendix | 46 | 2 |
| Methodology | 46 | 1 |
| Coverage | 46 | 1 |
| Secondary Research | 46 | 1 |
| Primary Research | 46 | 1 |
| Expert Panel Validation | 46 | 1 |
| Contact Us | 46 | 1 |
| Disclaimer | 47 | 1 |